秋水仙碱对肺切除术后胸腔积液的影响:一项随机盲法安慰剂对照可行性试验
该研究为COP-AF先导试验的子研究,在2个三级中心纳入100例肺切除患者,随机接受秋水仙碱0.6 mg每日两次(n=49)或安慰剂(n=51)共10天。结果显示秋水仙碱组术后40小时引流量(550.9 ml)显著少于安慰剂组(741.3 ml,P=0.039),术后第2天引流量亦显著减少(583.8 vs 763.3 ml,P=0.039),但拔管时间与住院时长无差异。
要点
- 肺切除术后秋水仙碱组40小时胸腔引流量550.9 ml,显著低于安慰剂组741.3 ml(P=0.039)。
- 秋水仙碱组术后第2天引流量583.8 ml,显著低于安慰剂组763.3 ml(P=0.039)。
- 两组拔管时间与住院时长无显著差异。
核心结论
- 口服秋水仙碱可能有效减少肺切除术后胸腔引流量,可考虑用于术后大量胸腔积液高风险患者。
- 需要一项完整规模的前瞻性安慰剂对照随机试验来评估肿瘤性肺切除围术期秋水仙碱给药的临床意义。
研究设计与样本
- COP-AF先导试验的子研究,为盲法随机安慰剂对照可行性试验。
- 2014年4月至2015年4月在2个三级中心纳入100例接受肺切除的患者。
- 秋水仙碱组49例接受口服秋水仙碱0.6 mg每日两次共10天,安慰剂组51例接受安慰剂每日两次共10天。
- 主要结局为总胸腔引流量,按标准化方案于术后前2天每8小时记录一次。
主要发现
- 仅1例患者未完成试验。
- 术后40小时平均胸腔引流量秋水仙碱组为550.9 ml,安慰剂组为741.3 ml(P=0.039)。
- 术后第2天平均胸腔引流量秋水仙碱组为583.8 ml,安慰剂组为763.3 ml(P=0.039),此后亦显著少于安慰剂组。
- 平均拔管时间秋水仙碱组为6.8天,安慰剂组为5.9天(P=0.585)。
- 平均住院时长秋水仙碱组为7.4天,安慰剂组为6.9天(P=0.641)。
临床怎么用
- 作者认为口服秋水仙碱可能有效减少肺切除术后胸腔引流量,可考虑用于术后大量胸腔积液高风险患者。
- 作者提出需要完整规模的前瞻性安慰剂对照随机试验来评估肿瘤性肺切除围术期秋水仙碱给药的临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This substudy of the colchicine for prevention of perioperative atrial fibrillation (COP-AF) pilot trial seeks to assess the effect of colchicine administration on the volume of postoperative pleural drainage, duration of chest tube in situ and length of stay following lung resection. METHODS: Between April 2014 and April 2015, 100 patients undergoing lung resection at 2 tertiary care centres participated in a pilot blinded randomized trial comparing perioperative twice daily 0.6 mg of colchicine orally (n = 49) or placebo (n = 51) twice daily for 10 days. The primary outcome was total pleural drainage volume, which was recorded in 8-h intervals for the first 2 postoperative days per standardized protocol. RESULTS: Only 1 patient did not complete the trial. The mean volume of pleural drainage at 40-h mark postoperation was significantly less in the colchicine group (550.9 ml) compared with the placebo group (741.3 ml, P = 0.039). Compared with the placebo group, the colchicine group showed significantly less mean pleural drainage on postoperative Day 2 (583.8 vs 763.3 ml, P = 0.039) and beyond. There were no differences in mean time to chest tube removal (6.8 days for the colchicine group vs 5.9 days for the placebo group, P = 0.585) and mean hospital length of stay (7.4 vs 6.9 days, P = 0.641). CONCLUSIONS: Oral colchicine is potentially effective in diminishing the amount of pleural drainage following lung resection and can be considered in patients at high risk of large postoperative pleural effusion. A full-scale, prospective placebo-controlled randomized trial is needed to assess the clinical significance of perioperative colchicine administration following oncological lung resection.
引用
- Agzarian J, Bessissow A, Srinathan S, et al. The effect of colchicine administration on postoperative pleural effusion following lung resection: a randomized blinded placebo-controlled feasibility pilot study. Eur J Cardiothorac Surg. 2018. PMID: 29186389. doi:10.1093/ejcts/ezx401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。